Novonesis delivered strong organic sales growth of 7% in 2025

Core Insights - Novonesis reported strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% for the year 2025, with expectations for continued growth in 2026 [1][2][3] Financial Performance - The company achieved broad-based organic sales growth of 7% in 2025, with a Q4 growth of 4%. The exit from certain countries negatively impacted growth by approximately 1 percentage point [2] - The Food & Health segment saw an 8% organic sales growth, while the Planetary Health segment achieved 6% organic sales growth, with notable double-digit growth in Energy [2] - Emerging Markets grew 9% organically, while Developed Markets grew 6% [3] - The adjusted EBITDA margin increased to 37.1%, up by 100 basis points from the previous year, despite currency headwinds [3] - Adjusted net profit rose by 17% [3] Cash Flow and Dividends - Free cash flow before acquisitions was EUR 770.4 million, representing 19% of sales [4] - A proposed dividend of DKK 4.25 per share was announced, with a pay-out ratio of 58.4% of adjusted net profit for 2025 [4] Product Innovation and Sustainability - The company launched 33 new products in 2025, contributing to 25% of total sales from innovations launched over the last five years [4] - Novonesis achieved all six environmental and social targets for 2025 and is on track for future commitments [4] 2026 Outlook - The company anticipates organic sales growth between 5-7% for 2026, with a good start to the year expected [5] - The outlook includes a potential negative impact of approximately 1 percentage point from exiting certain countries, but also includes positive contributions from pricing and sales synergies [5] - The adjusted EBITDA margin is expected to be between 37-38%, with anticipated margin expansion despite currency headwinds [5]